In short
BW-20805 is currently being studied as a potential treatment for Hereditary Angioedema (HAE), a rare genetic condition that causes sudden episodes of swelling in various parts of the body. This Phase 2, open-label, multicenter clinical trial aims to evaluate the efficacy and safety of BW-20805 in adult patients with HAE. The study explores different dosing schedules and amounts of the drug administered through subcutaneous (under the skin) injections. Researchers are particularly interested in measuring how well BW-20805 works in reducing the frequency of HAE attacks and assessing its safety profile over an extended treatment period.
Key points
- BW-20805 is being investigated in a Phase 2 clinical trial for treating Hereditary Angioedema (HAE), a rare genetic condition causing painful and potentially dangerous swelling episodes. The study examines three different dosing regimens of BW-20805 administered as subcutaneous injections: 600mg every 24 weeks, 300mg every 24 weeks, and 300mg every 12 weeks. The primary goal is to determine how effectively the drug reduces monthly HAE attacks by comparing attack rates before and during treatment up to Day 169. Researchers are also monitoring safety and tolerability over the extended study period of up to 96 weeks, providing valuable insights into this potential new HAE treatment option.
At a glance
- Trial Type
- Phase 2, open-label, multicenter study
- Medication
- BW-20805
- Condition
- Hereditary Angioedema (HAE)
- Treatment Groups
- - BW-20805 600 mg every 24 weeks; - BW-20805 300 mg every 24 weeks; - BW-20805 300 mg every 12 weeks
- Administration Method
- Subcutaneous (SC) injection
- Primary Outcome
- Change in monthly HAE attack rate from baseline to Day 169
- Secondary Outcome
- Safety and tolerability assessment through monitoring adverse events for up to 96 weeks
- Study Duration
- Up to 673 days (approximately 96 weeks)
What is BW-20805?
BW-20805 is an investigational medication being studied for the prevention of attacks in people with Hereditary Angioedema (HAE). This drug is currently in Phase 2 clinical trials, which means it is still being tested to determine its effectiveness and safety before it can be approved for general use by patients. The drug is being developed as a prophylactic treatment, which means it's designed to prevent HAE attacks from occurring rather than treating them once they've already started.
Understanding Hereditary Angioedema (HAE)
Hereditary Angioedema is a rare genetic disorder that causes episodes of severe swelling (edema) in various body parts, including the hands, feet, face, airway, and intestinal tract. These swelling attacks can be painful, disfiguring, and even life-threatening if they affect the airway. HAE is typically caused by a deficiency or dysfunction of a blood protein called C1 inhibitor, which normally helps regulate several complex processes in the blood.
Unlike allergic reactions, HAE attacks do not respond to antihistamines, epinephrine, or corticosteroids. The unpredictable nature of HAE attacks can significantly impact a person's quality of life, making preventive treatments particularly valuable for patients.
Current Clinical Trial
BW-20805 is being evaluated in "A Phase 2, Open-label, Multicenter Study to Assess the Efficacy and Safety of BW-20805 in Adult Subjects With Hereditary Angioedema." This means:
- Phase 2: The drug has passed initial safety testing in humans (Phase 1) and is now being tested in a larger group of people with HAE to see if it works and to further evaluate its safety.
- Open-label: Both the researchers and participants know which treatment is being administered (as opposed to a blinded study where participants don't know if they're receiving the actual drug or a placebo).
- Multicenter: The study is being conducted at multiple clinical sites, likely across different regions or countries.
- Adult Subjects: The study is enrolling adult patients diagnosed with HAE.
Dosing Regimens Under Investigation
The clinical trial is evaluating three different dosing regimens of BW-20805:
- 600 mg every 24 weeks: This group receives a 600 mg dose of BW-20805 administered subcutaneously (under the skin) every 24 weeks from Day 1 to Day 673 of the study.
- 300 mg every 24 weeks: This group receives a 300 mg dose of BW-20805 administered subcutaneously every 24 weeks from Day 1 to Day 169, and then from Day 337 to Day 673.
- 300 mg every 12 weeks: This group receives a 300 mg dose of BW-20805 administered subcutaneously more frequently - every 12 weeks from Day 1 to Day 589.
By testing different doses and administration schedules, researchers aim to determine which regimen provides the best balance of effectiveness and convenience for patients with HAE.
Effectiveness Measurements
The primary goal of the study is to determine how well BW-20805 works at preventing HAE attacks. Specifically, researchers are measuring the "change in time-normalized monthly (per 4 weeks) HAE attack rate from baseline to Day 169." This means they're comparing:
- How many HAE attacks a participant experienced in a typical month before starting the treatment (baseline)
- How many HAE attacks the same participant experiences per month during the first 169 days of treatment
A significant reduction in the frequency of attacks would suggest that BW-20805 is effective as a preventive treatment for HAE.
Safety Monitoring
An important secondary goal of the study is to evaluate the safety and tolerability of BW-20805. Researchers are tracking the "incidence and severity of SAEs and AEs up to 96 weeks" across the main study period, extension study period, and the whole study.
In this context:
- SAEs refers to Serious Adverse Events - any medical occurrences that result in death, are life-threatening, require hospitalization, cause persistent or significant disability, or birth defects.
- AEs refers to Adverse Events - any unfavorable and unintended sign, symptom, or disease that occurs while a person is in the clinical trial, whether or not it's related to the treatment being studied.
This extensive safety monitoring is crucial for determining whether BW-20805 can be safely used by patients with HAE in the long term.
Administration Method
BW-20805 is administered as a subcutaneous (SC) injection. This means the medication is injected just under the skin, rather than into a muscle (intramuscular) or vein (intravenous). Subcutaneous injections are generally less painful than other injection types and can often be self-administered by patients after proper training, which would be convenient for a long-term preventive treatment.
The long intervals between doses (either 12 or 24 weeks, depending on the study group) suggest that if approved, BW-20805 might offer patients with HAE a convenient dosing schedule that requires infrequent administration while still providing continuous protection against HAE attacks.